ASSESSMENT OF THE VALUE OF TREATMENT OF ANEMIA IN CHRONIC RENAL FAILURE PATIENTS ON REGULAR HEMODIALYSlS BY INTRAVENOUS IRON

Abstract

Anemia is the most common hematological abnormality• in patients with chronic renal failure. Iron deficiency is an important factor in the pathogenesis of this disease.

The aim of the present work is to study the role of intravenous iron therapy in correction of anemia in regular hemodialysis patients in comparison to oral iron therapy.

To fulfil this aim 63 stable hemodialysis patient all of them were suffering from sever to moderate anemia and were not under any form of replacement therapy (i.e. neither EPO nor iron}were selected and divided into two groups.

The first group, contain 36 patients (21 male and 15 female) that received intravenous iron saccharate [Ferric hydroxide saccharate (Ferosac, 100 mg/5ml) of SPIMACO, Saudi Arabia]. The second group, contain 27 patients (15 male and 12 female) that received oral iron (Ferrous fumarate 350 mg that has content of elemental iron 33%, Hemoton, of Glaxo Wellcome). The patients of either group were on the same form of the treatment for three months.